Clinical relevance of PM-1 antibody and physiochemical characterization of PM-1 antigen.
Using an improved immunodiffusion test with partially purified antigen, PM-1 antibody was identified in the serum of 18 patients. In 67% this system was associated with a polymyositis-scleroderma overlap, it occurred less frequently in polymyositis, dermatomyositis and scleroderma, and was not detected in other rheumatic diseases. The predominant clinical features of PM-1 positive patients were muscle weakness, sclerodactyly, Raynaud's phenomenon and pulmonary disease; widespread sclerodermatous features with infrequent. Characterization of the PM-1 antigen showed it to be a heat sensitive, trypsin sensitive acidic protein associated with the cell nucleus and possibly with nucleoli.
D000974:Antibodies, Antinuclear / Q000032:analysis*; D000918:Antibody Specificity; D000937:Antigen-Antibody Reactions; D000941:Antigens / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D004247:DNA / Q000276:immunology; D006801:Humans; D008970:Molecular Weight; D009220:Myositis / Q000276:immunology*; D020733:RNA, Small Cytoplasmic; D012216:Rheumatic Diseases / Q000276:immunology; D012261:Ribonucleoproteins; D017411:Ribonucleoproteins, Small Nuclear; D012595:Scleroderma, Systemic / Q000276:immunology*; D055517:snRNP Core Proteins; D000097585:SS-B Antigen; D000099207:SS-A Antigen
D000974:Antibodies, Antinuclear; D000941:Antigens; D001324:Autoantigens; D004247:DNA; D020733:RNA, Small Cytoplasmic; D012261:Ribonucleoproteins; D017411:Ribonucleoproteins, Small Nuclear; D055517:snRNP Core Proteins; D000097585:SS-B Antigen; D000099207:SS-A Antigen; C116006:RO60 protein, human